^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
nilvanstomig (ZG005)
i
Other names: ZG005, ZG 005, ZG-005, GS14
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Suzhou Zelgen
Drug class:
PD1 inhibitor, TIGIT inhibitor
Related drugs:
3d
ZG005 combination hydrochloride gilteritinib tablets in patients with relapsed or refractory lymphoma: a multicentre, open-label, dose-exploration and dose-expansion phase I/II clinical study. (ChiCTR2500114728)
P1/2, N=60, Recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
New P1/2 trial
|
Xospata (gilteritinib) • giredestrant (RG6171) • nilvanstomig (ZG005) • ravoxertinib (RG7842)
28d
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov)
P1/2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
nilvanstomig (ZG005)
29d
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=50, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
nilvanstomig (ZG005)
29d
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=350, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
alveltamig (ZG006) • nilvanstomig (ZG005)
29d
Study of ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P2, N=100, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
nilvanstomig (ZG005)
29d
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
ZGGS18 • nilvanstomig (ZG005)
29d
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer (clinicaltrials.gov)
P1/2, N=120, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
Avastin (bevacizumab) • nilvanstomig (ZG005)
5ms
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=153, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
nilvanstomig (ZG005)
6ms
Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P2 trial
|
cisplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • nilvanstomig (ZG005)
6ms
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer (clinicaltrials.gov)
P1/2, N=120, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
Avastin (bevacizumab) • nilvanstomig (ZG005)
7ms
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
P1/2, N=350, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
alveltamig (ZG006) • nilvanstomig (ZG005)
10ms
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
New P1/2 trial
|
ZGGS18 • nilvanstomig (ZG005)
Share via
